Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Carlyle Group Unveils Alarming Job Market Trends Amid Shutdown
- Transforming Investments: Norfolk Southern's Growth Over Two Decades
- How $100 in Western Digital Could Have Grown Over 5 Years
- ScaleNorth Celebrates Victory as NetSuite Partner of the Year
- Cal Mukumoto Named Executive Director of Intertribal Timber Council
- The Financial Growth of IDEXX Laboratories Over 15 Years
- Sprig Unveils Innovative New Headquarters to Transform Dentistry
- Elevate Your Oral Care: MySmile's Prime Day Specials
- Klotho Neurosciences Moves Forward After Letter of Intent Expiration
- Wabash to Host Earnings Call for Q3 2025 Financial Results
- Volaris Unveils Its Forward-Thinking 2024 Annual Report
- Significant Growth of Taylor Morrison Home Over 5 Years
- Exploring Five-Year Returns of Bank of New York Mellon Stock
- Congresswoman's Delayed Stock Trades Raise Eyebrows
- Investigation into Alto Neuroscience: What You Need to Know
- Calamos Launches New Bitcoin ETFs with Downside Protection
- Understanding the Dynamics Behind UiPath Inc's Stock Performance
- Cherokee Federal Expands Digital Services Through Strategic Acquisition
- Calamos Investments Launches Bitcoin Protection ETFs with Caps
- Grupo Rotoplas Achieves Milestone as Water-Responsible Leader
- ISC2's Certified in Cybersecurity Certification Celebrates Growth
- Gneuton Innovations: Revolutionizing Water Sustainability in AI
- Cyteph Advances Cancer Treatment with CYT-101 Clinical Trial
- Paul Gauguin Cruises Honored Again as Best Small Cruise
- Understanding Joby Aviation's Recent Stock Price Drop
- Fifth Third Bancorp Investigation: An Insight for Shareholders
- Comerica Incorporated Faces Investigation Over Fifth Third Deal
- EQV Ventures and Presidio Petroleum Secure Merger Move Forward
- Investigation Launched Into Veeco Instruments: The Deal Examined
- Rocket Lab Announces New Missions in Partnership with iQPS
- Exploring the Investigation of Ryvyl Inc. for Shareholder Justice
- Investigation Launched on Cool Company Ltd. (NYSE: CLCO)
- Understanding the Axcelis Technologies, Inc. Merger Proposal
- BioVaxys Launches Innovative Financing Initiative for Growth
- Kirtland Credit Union Provides Relief Amid Federal Shutdown
- Avanti Revolutionizes K-12 Educator Learning Experience
- Legal Action Following Chevron Refinery Explosion Incident
- Copa Holdings Reveals Upcoming Earnings Call and Webcast Schedule
- Rocky Shore Gold Completes Final Phase of Successful Offering
- Stockwik Secures Strategic Partnership with ENDI Corp Through Share Issue
- Primaris REIT Secures $250 Million for Green Initiatives
- Join the Autumn Celebration at Skyview's Home Tour
- Exploring the Financial Growth of UnitedHealth Group Stock
- Intouch Insight Ltd. Exciting Presentation at MicroCap Showcase
- Explore the Fall Home Tour at Skyview at High Point
- Regal Rexnord's Upcoming Earnings and Innovations Overview
- BioVaxys Technology Launches Attractive Private Placement Offering
- Examining the Growth of the AHR Agonists Market in Healthcare
- The Explosive Growth of AI SDR Market to Reach $47.12 Billion
- Rocket Lab Expands Partnership with iQPS for Future Missions